Adrenal Suppression in Children Treated With Oral Viscous Budesonide for Eosinophilic Esophagitis.

Abstract

We sought to determine the prevalence of adrenal suppression (AS) in children with eosinophilic esophagitis treated with oral viscous budesonide (OVB). This was a retrospective review of a quality assurance initiative, whereby all children in our center treated with OVB for ≥3 months were referred over an 18-month time frame for endocrine assessment including 1 μg adrenocorticotropic hormone stimulation test. Fourteen of 19 children complied with the referral; of these 14 children, 6 (43%) had suboptimal stimulated cortisol (range 343-497 nmol/L, mean [±SD] 424.7 nmol/L [±52.4], normal ≥500 nmol/L). There was no significant association to treatment duration, dose, or concomitant use of inhaled/nasal corticosteroids. This study suggests that children treated with OVB may be at risk for AS.

• Authors: Shira Harel, Brenden E Hursh, Edmond S Chan, Vishal Avinashi, Constadina Panagiotopoulos
• Journal: Journal of pediatric gastroenterology and nutrition (J Pediatr Gastroenterol Nutr) Vol. 61 Issue 2 Pg. 190-3 (Aug 2015) ISSN: 1536-4801 [Electronic] United States
• PMID: 25950088 (Publication Type: Journal Article)

Chemical References

• Glucocorticoids
• Budesonide
• Adrenocorticotropic Hormone
• Hydrocortisone

Topics

• Adolescent
• Adrenal Insufficiency (chemically induced, diagnosis, epidemiology)
• Adrenocorticotropic Hormone (administration & dosage)
• Asthma (complications)
• Budesonide (administration & dosage, adverse effects, therapeutic use)
• Child
• Child, Preschool
• Eosinophilic Esophagitis (drug therapy)
• Female
• Glucocorticoids (adverse effects, therapeutic use)
• Humans
• Hydrocortisone (blood)
• Male
• Retrospective Studies